Report cover image

Artificial Blood Market - 2024-2031

Publisher DataM Intelligence 4Market Research LLP
Published Feb 19, 2026
Length 180 Pages
SKU # DTAM21021260

Description

MARKET SIZE

Global Artificial Blood Market reached US$ 3760.00 million in 2023 and is expected to reach US$ 7194.83 million by 2031, growing at a CAGR of 8.7% during the forecast period 2024-2031.

While true blood performs different functions, artificial blood is designed to transport oxygen and carbon dioxide through the body. Based on the type of artificial blood it can be produced in different ways including synthetic production, chemical isolation, or recombinant biochemical technology.

The advantages of artificial blood include providing critical benefits over allogenic blood transfusions by delivering increased oxygen-carrying capacity, saving time in trauma cases and battlefield scenarios, higher life than regular blood, minor chances of the disease spreading, and the ability to manufacture larger quantities of blood. Artificial blood is available in the market in terms of hemoglobin-based oxygen carriers and perfluorocarbon emulsions.

MARKET SCOPE

Metrics Details
CAGR 8.7%
Market Size Available for Years 2022-2031
Estimation Forecast Period 2024-2031
Revenue Units Value (US$ Mn)
Segments Covered Product Type, Source, Process, Application, End-User
Regions Covered North America, Europe, Asia-Pacific, South America, and Middle East & Africa
Largest Region North America
Fastest Growing Region Asia-Pacific
Report Insights Covered Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights.

For more details on this report – Request for Sample (https://www.datamintelligence.com/download-sample/artificial-blood-market)

MARKET DYNAMICS: DRIVERS & RESTRAINTS

RISING ADVANCEMENTS IN RESEARCH AND DEVELOPMENT

The rising research and development are expected to drive the market growth. Ongoing research is focused on addressing safety issues of artificial blood, such as immunological reactions and toxicity. Advancements in R&D can result in safer blood replacements with fewer adverse effects, increasing physician and patient acceptance of their use. Researchers are focusing on the development of products that could mimic the blood with fewer side effects.

For instance, in November 2022, a world-first clinical trial (https://www.datamintelligence.com/research-report/clinical-trials-market) funded and supported by NIHR started giving lab-grown red blood cells to people. The RESTORE clinical trial (REcovery and survival of STem cell Originated REd cells) was initiated by the NIHR Blood and Transplant Research Unit in Red Blood Cell Products.

Additionally, on July 18, 2024, Bioxytran, Inc. announced a Joint Venture with the Heme Foundation to develop a Universal Oxygen Carrier (“UOC”) as an alternative to blood transfusions.

And, on July 27, 2024, Nara Medical University stated that it will begin a clinical study of artificial red blood cells that can be stored for transfusions in times of emergency in Japan by next March 2025.

ADVERSE EFFECTS OF ARTIFICIAL BLOOD

Adverse effects of hemoglobin-based oxygen carriers include hypertension, abdominal pain, skin rash, diarrhea, jaundice, hemoglobinuria, oliguria, fever, stroke, and laboratory abnormalities such as an increase in lipase. These adverse reactions could reduce the adoption of artificial blood in surgical procedures and for transfusions.

MARKET SEGMENT ANALYSIS

The global artificial blood market is segmented based on product type, source, process, application, end-user, and region.

HEMOGLOBIN-BASED OXYGEN CARRIERS SEGMENT IS EXPECTED TO DOMINATE THE MARKET SHARE

Hemoglobin-based oxygen carriers segment is expected to hold a significant position in the market share due to a variety of factors. HBOCs have been developed to efficiently transport and release oxygen, which is comparable to the function of natural hemoglobin in red blood cells. This makes them extremely effective for oxygen delivery, especially in situations of emergency.

HBOCs can be employed in a variety of medical settings, including operations, injuries, and anemia therapies. Their ability to adapt improves their commercial potential across numerous applications. Significant R&D investment is being made to improve the efficacy and safety features of HBOCs, resulting in advances that can increase their adoption in clinical settings. Thus, the above factors are expected to hold a significant position in the market share.

MARKET GEOGRAPHICAL SHARE

NORTH AMERICA IS EXPECTED TO HOLD A SIGNIFICANT POSITION IN THE ARTIFICIAL BLOOD MARKET SHARE

North America dominates the global artificial blood market during the forecast period owing to the rise in trauma deaths due to excessive blood loss before admission, and an increase in the prevalence of anemia and blood-related disorders across the region leading to the development of novel artificial blood.

The rising studies in the development of artificial blood in the region to substitute the original human blood and use it for the transfusion processes in the anemic and other patients are expected to drive market growth in the region.

For instance, according to a publication by UMSOM, UMSOM will manage the $46.4 million four-year research project administered by the Defense Advanced Research Projects Agency (DARPA), in collaboration with the University of Maryland School of Pharmacy (UMSOP) and more than a dozen universities and biotech companies. A Physician-scientist of UMSOM will head the new federally-funded research program to develop and test a whole blood product, storable at room temperature, that can be used to transfuse wounded soldiers in the field within 30 minutes of injury, potentially saving thousands of lives

MARKET SEGMENTATION

By Product Type

• Hemoglobin-based Oxygen Carriers
• Perfluorocarbon Emulsion
By Source

• Human Hemoglobin
• Animal Hemoglobin
• Stem Cells
• Synthetic Polymers
• Microorganisms
• Others
By Process

• Synthetic Production
• Chemical Isolation
• Recombinant Biochemical Technology
By Application

• Anemia
• Organ Transplantation
• Injuries & Trauma
• Cardiovascular Diseases
• Maternal Conditions
• Others
By End-User

• Hospitals
• Clinics
• Blood Banks
• Research Institutes
• Others
By Region

• North America
• The U.S.
• Canada
• Mexico
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe
• South America
• Brazil
• Argentina
• Rest of South America
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
• Middle East and Africa

MARKET COMPETITIVE LANDSCAPE

The major global players in the market include Hemarina, KaloCyte (https://kalocyte.com/), Inc., SpheriTech Limited, and Hemoglobin Oxygen Therapeutics LLC among others.

Why Purchase the Report?

• To visualize the global artificial blood market segmentation based on product type, source, process, application, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of artificial blood market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global artificial blood market report would provide approximately 53 tables, 47 figures, and 176 pages.

TARGET AUDIENCE 2025

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

TRENDING REPORTS:

Collagen and Gelatin Market (https://www.datamintelligence.com/research-report/collagen-and-gelatin-market)

Optical Genome Mapping Market (https://www.datamintelligence.com/research-report/optical-genome-mapping-market)

Table of Contents

180 Pages
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product Type
3.2. Snippet by Source
3.3. Snippet by Process
3.4. Snippet by Application
3.5. Snippet by End-User
3.6. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising advancements in research and development
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Adverse effects of artificial blood
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. By Product Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
6.1.2. Market Attractiveness Index, By Product Type
6.2. Hemoglobin-based Oxygen Carriers*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Perfluorocarbon Emulsion
7. By Source
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
7.1.2. Market Attractiveness Index, By Source
7.2. Human Hemoglobin*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Animal Hemoglobin
7.4. Stem Cells
7.5. Synthetic Polymers
7.6. Microorganisms
7.7. Others
8. By Process
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Process
8.1.2. Market Attractiveness Index, By Process
8.2. Synthetic Production*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Chemical Isolation
8.4. Recombinant Biochemical Technology
9. By Application
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.1.2. Market Attractiveness Index, By Application
9.2. Anemia*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Organ Transplantation
9.4. Injuries & Trauma
9.5. Cardiovascular Diseases
9.6. Maternal Conditions
9.7. Others
10. By End-User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Clinics
10.4. Blood Banks
10.5. Research Institutes
10.6. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.2.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
11.2.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Process
11.2.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.3.1. The U.S.
11.2.3.2. Canada
11.2.3.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.3.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
11.3.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Process
11.3.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.4.1. Germany
11.3.4.2. UK
11.3.4.3. France
11.3.4.4. Italy
11.3.4.5. Spain
11.3.4.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.4.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
11.4.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Process
11.4.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.4.1. Brazil
11.4.4.2. Argentina
11.4.4.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
11.5.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Process
11.5.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.4.1. China
11.5.4.2. India
11.5.4.3. Japan
11.5.4.4. South Korea
11.5.4.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
11.6.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Process
11.6.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Hemarina *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. KaloCyte, Inc.
13.3. SpheriTech Limited
13.4. Hemoglobin Oxygen Therapeutics LLC. (*LIST NOT EXHAUSTIVE)
14. Appendix
14.1. About Us and Services
14.2. Contact Us

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us